ArticleAnnals of gastroenterology2017

Efficacy and safety profile of boceprevir- or telaprevir-based triple therapy or dual peginterferon alfa-2a or alfa-2b plus ribavirin therapy in chronic hepatitis C: the real-world PegBase observational study.

Alessandra Mangia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.